Healthcare Industry News: M. D. Anderson Cancer Center
News Release - March 16, 2010
NCCN Guidelines Expand Their Reach to JapanThe National Comprehensive Cancer Network® (NCCN®) recently announced that select NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™), the most widely used guidelines in oncology practice around the globe, are being translated into Japanese.
FORT WASHINGTON, Pa.--(HSMN NewsFeed)--The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) have been further recognized as the global standard in oncology with the announcement that select NCCN Guidelines™ are being translated into Japanese. The Translational Research Informatics Center (TRI) Foundation for Biomedical Research and Innovation, under the supervision of the Japanese Society for Cancer of the Colon and Rectum, has translated the NCCN Guidelines for Colon Cancer and Rectal Cancer, which are now available online. In addition, translations of the NCCN Guidelines for Anal Carcinoma and Colorectal Cancer Screening will be published shortly.
“NCCN is pleased to be able to collaborate with clinicians in Japan in determining appropriate and effective avenues of care for their oncology patients,” said William T. McGivney, PhD, Chief Executive Officer, NCCN. “As the arbiter of high-quality cancer care, NCCN remains dedicated to enhancing our international relationships to improve the quality, effectiveness, and efficiency of oncology practice so patients worldwide can live better lives.”
Cancer is the leading cause of death in Japan, with one person out of three dying of the disease according to the Japan Cancer Society. Colon cancer is the third leading cause of cancer deaths among the Japanese following lung and stomach cancer.
“In Japan, more than 500,000 people are diagnosed with cancer each year and more than 335,000 die from the disease every year,” said Masanori Fukushima, MD, PhD, Professor Emeritus, Kyoto University, Director and Chairman of TRI. “Consequently, by aligning with NCCN to provide our clinicians with treatment recommendations developed by world-renowned experts in cancer, we look to improve the care provided to patients and impact the number of cancer survivors in Japan.”
NCCN’s international collaborations continue to grow fostered by the demand for the development and publication of foreign editions of the NCCN Guidelines. These editions are either direct translations of the NCCN Guidelines into a foreign language, as with Japan, or modified versions of the NCCN Guidelines to take into consideration metabolic differences in populations, accessibility of technology, and/or the regulatory status of health care technologies used in cancer management in the specified country. Foreign editions of the NCCN Guidelines are developed by the host country’s oncology thought leaders in conjunction with NCCN Guidelines Panel Chairs or Members to ensure consistency and accuracy.
Additional Japanese translations of the NCCN Guidelines in the areas of urological cancers will be developed throughout the coming year.
The NCCN Guidelines are developed and updated through an evidence-based process with explicit review of the scientific evidence integrated with expert judgment by multidisciplinary panels of physicians from NCCN Member Institutions. The most recent versions of all the NCCN Guidelines are available free of charge at NCCN.org.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.
The NCCN Member Institutions are: City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Comprehensive Cancer Center, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/University of Tennessee Cancer Institute, Memphis, TN; Stanford Comprehensive Cancer Center, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; UNMC Eppley Cancer Center at The Nebraska Medical Center, Omaha, NE; The University of Texas M. D. Anderson Cancer Center, Houston, TX; and Vanderbilt-Ingram Cancer Center, Nashville, TN.
For more information, visit NCCN.org.
Source: National Comprehensive Cancer Network
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.